Suggestions

PIII · NASDAQ

P3 HEALTH PARTNERS INC

Private beta

Sector unavailable · Industry unavailable

$8.43

+0.84%

Close on Sep 11, 2026

Insufficient Data

Updated 12/18/2023

Long-term research evidence only. No price targets, no trading signals, no recommendations.

Investment Report Card

P3 HEALTH PARTNERS INC

Sector unavailable · Data confidence limited

No Suggested Investment Score today

Risk Intelligence is unavailable

Risk Intelligence

Core Model

Not Available

Insufficient Data

How strong and defensively sound is the company?

This reading is not available for this company yet.

Long-Term Potential

Research Model

Not Available

Insufficient Data

Does the business have the characteristics needed to create value over many years?

This reading is not available for this company yet.

Fundamental Momentum

Research Model

Not Available

Insufficient Data

Is the underlying business getting stronger or weaker?

This reading is not available for this company yet.

Ownership Intelligence

Supplemental Intelligence

Not Available

Positive disclosed activity

What are important owners actually doing?

This reading is not available for this company yet.

Valuation Intelligence

Research Model
A+

98 / 100

Very Attractive

Is today's price reasonable?

Among the strongest readings on this measure — and valuation is researched separately from the Suggested Investment Score.

Capital Returns Intelligence

Research Model
C−

58 / 100

Favorable Capital Returns

How effectively does the company reward shareholders?

Around the middle of the covered universe — and capital returns are researched separately from the Suggested Investment Score.

Why it stands out

  • More disclosed holders are new or increasing than reducing or exiting.
  • Attractive valuation: the stock reads 98 out of 100 on Valuation Intelligence (Very Attractive) relative to its own history and comparable companies.

What holds it back

No weakening evidence is recorded in today's readings.

Long-term view

Long-Term Potential is not available for this company, so no long-term reading is shown.

Ownership view

No disclosed ownership reading is available at the required confidence, so ownership is left blank rather than estimated.

Valuation view

P3 HEALTH PARTNERS INC reads 98 out of 100 on Valuation Intelligence, recorded as Very Attractive. The stock currently trades below most of its own recent valuation history and below comparable companies. This describes the price being paid relative to the company's financials — it is not a forecast and not a fair value. Valuation Intelligence is a research model and contributes nothing to the Suggested Investment Score or the daily ranking.

Capital returns view

P3 HEALTH PARTNERS INC reads 58 out of 100 on Capital Returns Intelligence (Favorable Capital Returns), reflecting a share count falling about 7.1% a year. Direct capital returns are limited because the company continues reinvesting most of its cash. Capital Returns Intelligence is a research model and contributes nothing to the Suggested Investment Score or the daily ranking.

What changed

No meaningful recorded changes in the stored history.

Risk Intelligence is a core model, Long-Term Potential, Fundamental Momentum, Valuation Intelligence and Capital Returns Intelligence are research models, and Ownership Intelligence is supplemental descriptive evidence. Valuation Intelligence and Capital Returns Intelligence each contribute 0% to the Suggested Investment Score. Nothing here is a recommendation.

Compare PIII with other companies

Appears in

Rule-based membership

Membership means the company satisfied a published rule on the latest research build. It is not a recommendation.

60-Second Brief

Too few stored readings exist for this company to summarise honestly.

Composite discovery model

Suggested Investment Score

Suggested Investment Score

Not currently in the Suggested Investment ranking

Risk Intelligence is unavailable. A composite score is only published when every required input is available for this company. Nothing is estimated to fill a gap, and exclusion from the ranking is not a sell instruction.

COMPOSITE DISCOVERY MODEL — RESEARCH STAGE · Ranking updated September 12, 2026

Researched separately

Valuation Intelligence 98 · Very Attractive

RESEARCH MODEL

Valuation Intelligence is currently researched separately and does not affect the Suggested Investment Score or daily ranking.

Researched separately

Capital Returns Intelligence 58 · Favorable Capital Returns

RESEARCH MODEL

Capital Returns Intelligence is researched separately and contributes 0% to the Suggested Investment Score, the daily rank or any ranking event.

Why this company scores the way it does

This company does not currently hold a stored Suggested Investment Score, so no contribution breakdown can be shown.

Stored snapshots only

What changed

Research-score history available since September 2026.

Stored research history does not yet cover a full 30 days comparison for this company.

A change is reported as meaningful at 8 score points, 5 rank places, or any change of research classification. Nothing here is a recommendation to buy or sell.

Learn the metrics on this page

Plain-English definitions, with the formula and the limitations of each measure.

Fifth research lens · outside the score

Valuation Intelligence

Valuation Intelligence

Is today's price reasonable?

Valuation Intelligence is currently researched separately and does not affect the Suggested Investment Score or daily ranking.

98/ 100

Very Attractive

RESEARCH MODEL
Good coverage

Compared with its history

97

Very Attractive

Is this company expensive or inexpensive compared with its own history?

Compared with peers

97

Very Attractive

How expensive is this stock compared with similar companies?

Earnings & cash flow

Not Available

How much financial output does an investor receive relative to the price paid?

No positive earnings or cash-flow yield is available, so this lens is not scored.

Growth-adjusted

100

Very Attractive

Does the company's growth help justify the valuation investors are paying?

P3 HEALTH PARTNERS INC reads 98 out of 100 on Valuation Intelligence, recorded as Very Attractive. The stock currently trades below most of its own recent valuation history and below comparable companies. This describes the price being paid relative to the company's financials — it is not a forecast and not a fair value.

Price data through September 11, 2026 · Financial data through the quarter ended June 30, 2026

Valuation history

Stored readings only. The dashed line is this company's own median for the selected measure.

Only one stored valuation reading exists so far, so there is nothing to chart yet. Valuation history builds forward from activation rather than being reconstructed.

Current EV/Sales 0.1x · own median 0.2x · peer median 1.5x

Valuation is inherently uncertain. A stock that appears inexpensive can continue falling, and a stock that appears expensive can continue rising. Valuation Intelligence provides context about the price investors are paying — it does not predict short-term market movements, and it never produces a fair value, a price target or a buy or sell range. Model VALUATION_INTELLIGENCE_V1.

Sixth research lens · outside the score

Capital Returns Intelligence

Capital Returns Intelligence

How effectively does the company reward shareholders?

Capital Returns Intelligence is researched separately and contributes 0% to the Suggested Investment Score, the daily rank or any ranking event.

58/ 100

Favorable Capital Returns

RESEARCH MODEL
Good coverage

Dividend Quality

Not Applicable — No Dividend

Dividend reliability

This company currently retains rather than distributes cash through dividends. Capital Returns Intelligence therefore places more emphasis on its other measurable shareholder-return behaviors according to the frozen V1 methodology.

Buyback Effectiveness

15

Limited Capital Returns

Do buybacks actually reduce shares?

No net share repurchases are recorded in the stored cash-flow statements.

Dilution Control

97

Exceptional Capital Returns

Is your ownership share protected?

Capital Return Sustainability

Not Available

Can the cash flow support it?

The company returned no measurable capital in the latest period, so there is nothing to sustain.

Shareholder Yield

89

Exceptional Capital Returns

Cash returned versus company value

P3 HEALTH PARTNERS INC reads 58 out of 100 on Capital Returns Intelligence (Favorable Capital Returns), reflecting a share count falling about 7.1% a year. Direct capital returns are limited because the company continues reinvesting most of its cash.

This company currently retains rather than distributes cash through dividends. Capital Returns Intelligence therefore places more emphasis on its other measurable shareholder-return behaviors according to the frozen V1 methodology.

No measurable cash was returned to shareholders through dividends or net repurchases in the latest stored statements.

Price data through September 11, 2026 · Financial data through the quarter ended June 30, 2026

Capital returns history

Stored readings only. History builds forward from activation rather than being reconstructed.

Only one stored reading exists for this measure so far, so there is nothing to chart yet.

Why higher yield isn't always better

A very high dividend yield may reflect a falling share price or an unsustainable payout. Capital Returns Intelligence emphasizes consistency and sustainability rather than simply rewarding the highest yield.

Why buybacks can be misleading

Announced or gross buyback spending does not always mean shareholders are gaining ownership. Companies can simultaneously issue shares through employee compensation or acquisitions. Suggested Investments therefore considers actual share-count changes alongside repurchase spending.

What these terms mean
Dividend Yield
The annual dividend relative to the current share price.
Payout Ratio
The share of company earnings used to pay dividends.
Free Cash Flow Payout
How much of the company's available cash is being used for dividends.
Share Repurchases
When a company buys back its own stock.
Dilution
When the number of shares increases, reducing each existing share's percentage ownership of the company.
Shareholder Yield
A combined view of dividends and net share repurchases relative to the company's market value.

Capital Returns Intelligence describes how a company returns capital to shareholders. It is not a measure of stock-price performance, it does not predict future returns, and a strong reading is never a recommendation to buy. Dividends and repurchases can be reduced or stopped at any time. Model CAPITAL_RETURNS_INTELLIGENCE_V1, contributing 0% to the Suggested Investment Score.

Stored daily snapshots only

Ranking history

Stored Suggested Investment ranking history
TodayNot rankedNo stored score
30 days agoNot rankedNo stored score
90 days agoNot rankedNo stored score
First suggestedNot yet suggested
Highest rankNot ranked

In the company’s own words

What this company does

We were incorporated in Delaware as Foresight Acquisition Corp. ("Foresight") on August 20, 2020. On December 3, 2021 (the "Closing Date"), we completed the Business Combinations (defined and discussed more fully below) with P3 Health Group Holdings, LLC, a Delaware limited liability company ("P3 Health Group Holdings") and we changed our name to P3 Health Partners Inc. Following the Business Combinations, we are organized in an "Up-C" structure, in which P3 Health Partners Inc. is the sole manager of P3 Health Group, LLC and directly owns approximately 46% of P3 Health Group, LLC as of December 31, 2025. Substantially all of the Company’s assets are held and operations are conducted by P3 LLC and its subsidiaries, and the Company’s only assets are equity interests in P3 LLC.

The Business Combinations were effected pursuant to (1) an agreement and plan of merger, dated as of May 25, 2021 (as amended, the "Merger Agreement"), by and among Foresight, P3 Health Group Holdings and Merger Sub, and (2) the transaction and combination agreement, dated as of May 25, 2021 (as amended, the "Transaction and Combination Agreement"), by and among Foresight, the Merger Corps, the Blockers, and the Blocker sellers (each term as defined in the Transaction and Combination Agreement), pursuant to which, among other things, P3 Health Group Holdings merged with and into Merger Sub (the "P3 Merger"), with Merger Sub as the surviving company, which was renamed P3 LLC, and the Merger Corps merged with and into the Blockers, with the Blockers as the surviving entities and wholly owned subsidiaries of Foresight (collectively, the "Business Combinations").

P3 is a patient-centered and physician-led population health management company. We strive to offer superior care to those patients that we serve. Founded and led by physicians, P3 is a team of doctors, clinicians and healthcare professionals with a shared passion for delivering value-based care ("VBC"). We believe our leadership team’s substantial experience in VBC and population health management, combined with our strong payor relationships, large community-based physician networks and custom technology platform uniquely position us to empower physicians, align incentives for healthcare providers and payors and improve the clinical outcomes for the communities we serve.

As fellow healthcare professionals, we understand the challenges physicians face when providing VBC. We have leveraged that expertise to build our "P3 Care Model." The key attributes that differentiate P3 include: 1) patient centricity, 2) physician leadership, and 3) our delegated/integrated care model. Tactically, we typically leverage the community’s existing healthcare infrastructure to build a strong network of local physicians. We primarily contract with local physicians to enter the P3 network using an affiliate model, rather than building and staffing our own clinics or acquiring individual practices. By doing so, we preserve the existing patient-physician relationship, allow physicians to maintain their independence and have a built-in patient panel on Day 1. We then align physician incentives and provide our team tools and technology to support our physician partners in a VBC system and care for the patients we have the honor and privilege to serve together. We augment these affiliate partnerships with employed Primary Care Physicians ("PCPs"), P3-operated clinics, and wellness centers. Furthermore, we offer a broad delegated care model in which we take on the responsibility to reshape the local healthcare market to provide high quality care for patients throughout the care continuum.

Quoted from the business section of this company’s 10-K filed March 26, 2026. Read the filing

Four distinct intelligence areas

The IA view

Risk Intelligence

Production core

41

Restricted

No prior period to compare

Business Quality qualification score from the locked IA Defensive Research Core. Price Risk stays a separate category and is never blended in.

As of Sep 11, 2026

Long-Term Potential

Research model

Insufficient Data

No prior period to compare

Durable business economics and reinvestment characteristics. Independent external validation is pending.

Fundamental Momentum

Research model

Insufficient Data

No prior period to compare

Direction and breadth of change in underlying business fundamentals. Not a price-momentum signal.

Elite Investor Activity

Supplemental

Insufficient Data

No prior period to compare

No tracked manager filings mapped to this company.

Intelligence history

Not enough stored history to chart PIII yet. A company needs at least two published research or ownership periods before a trend can be shown.

Share price

PIII price history

Closing prices adjusted for splits and dividends. Past prices do not indicate future results.

6M change
+184.8%
1Y change
-2.0%
3Y change
-93.0%
5Y change
-98.3%
Max change
-98.4%

Last stored close $8.43 · -2.0% over the selected range · 64 sessions shown

Balanced evidence

Why IA likes it

  • More disclosed holders are new or increasing than reducing or exiting.

Risk and uncertainty

What IA doesn’t like

  • No specific negative evidence is available. This is not evidence of low risk.

What would change our view

  • Business Quality falling below the frozen qualification threshold.
  • Price Risk moving to a less favorable category.
  • A sustained reversal in the Fundamental Momentum research evidence.
  • New material public ownership disclosures.

Public filings · descriptive only

Elite Investor Activity

Reporting holders

4

New holders

4

Increasing

0

Reducing

0

Exiting

0

Coverage

Excellent

Positive disclosed activity · Report period 2023-09-30 · Public 12/18/2023

ManagerChangePortfolio weightRankDisclosed

Insufficient high-confidence manager coverage.

Objective stored changes

What changed

No qualifying changes are recorded for this company in the stored research and filing history.

Ownership timeline

No high-confidence public ownership events are available.

General research only. Not personalized advice. Public filings may be delayed, amended, incomplete, or reflect positions that have changed since the reporting date.